Grand Theravac Life Science (Nanjing) Co., Ltd.

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 3
Hepatitis B virus antigens (HBsAg + HBcAg)Vaccine
Chronic Hepatitis B
Phase 1
—
Chronic Hepatitis B

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.